More on BMY

- Summary
- Chart
- Profile
- Historical


- Earnings (+24.5% Growth)
- Ratings (4.8 Score)
- Holders
- Dividends (2% Yield)
- FDA Archive


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (7/28/16)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

BMY Balance Sheet

Click line-items for a historical chart and %
Current Assets:
Cash and cash equivalents 2.64B
Marketable securities 1.66B
Receivables 4.96B
Inventories 1.34B
Deferred income taxes
Prepaid expenses and other 615M
Total Current Assets 11.22B
Property, plant and equipment 4.46B
Goodwill 6.88B
Other intangible assets 1.38B
Deferred income taxes 3.23B
Marketable securities 3.69B
Other assets 1.05B
Total Assets 31.89B
Current Liabilities:
Short-term borrowings 106M
Accounts payable 1.54B
Accrued expenses 4.31B
Deferred income 1.17B
Accrued rebates and returns
U.S. and foreign income taxes payable 472M
Dividends payable
Total Current Liabilities 7.6B
Pension, postretirement, and postemployment liabilities
Deferred income 606M
U.S. and foreign income taxes payable 852M
Other liabilities 1.69B
Long-term debt 6.59B
Total Liabilities 17.34B
Commitments and contingencies (Note 14) 0
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 5,268 in 2011 and 5,269 in 2010, liquidation value of $50 per share 0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2011 and 2010 221M
Capital in excess of par value of stock 1.5B
Accumulated other comprehensive loss -2.69B
Retained earnings 32.18B
Less cost of treasury stock - 500 million common shares in 2011 and 501 million in 2010 -16.82B
Total Bristol-Myers Squibb Company Shareholders' Equity 14.39B
Noncontrolling interest 165M
Total Equity 14.55B
Total Liabilities and Equity 31.89B